Inhaled nitric oxide in patients  with pulmonary embolism

Capellier, Gilles; Jacques, Thierry; Balvay, P.; Blasco, G.; Belle, Éric Van; Barale, F

doi:10.1007/s001340050461

Cited by 97 publications

(44 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study is the only report that compares the acute hemodynamiceffects of a pulse delivery system with a nasal cannula and those of a continuous delivery system with a mask in adult patients with precapillary pulmonary hypertension. Short-term inhaled NOtherapy has been tried in cases with various types of pulmonary hypertension including persistent pulmonary hypertension of the newborn (4-7), residual pulmonaryhypertension after cardiac surgery (8-1 2), adult respiratory distress syndrome (13,14), Eisenmenger syndrome (15,16), primary pulmonary hypertension ( 1 8), pulmonary thromboembolism (19,20), and rheumatic disease (21,22). These reports demonstrated that inhaled NOis an ideal pulmonary vasodilator for patients with pulmonary hypertension.…”

Section: Resultsmentioning

confidence: 99%

Hemodynamic Effects of Inhaled Nitric Oxide Using Pulse Delivery and Continuous Delivery Systems in Pulmonary Hypertension.

et al. 2002

View full text Add to dashboard Cite

Objective Inhaled nitric oxide (NO) has been used for pulmonary vasodilation therapy in patients with pulmonary hypertension. Inhaled NOfor awake and ambulatory patients, however, is unusual because it requires intubation or a tightly fitting facemask, and a large-scale delivery systemfor the safe management of toxic nitrogen oxides. Weundertook this study to investigate the possibility of using inhaled NOtherapy for awake and ambulatory patients with pulmonary hypertension.Methods Patients with pulmonary hypertension underwent cardiac catheterization and hemodynamicvariables were measured at the baseline, after inhaled NOusing our pulse delivery system, which involved a nasal cannula and a pulse device, and after inhaled NOusing a continuous delivery system.Patients or materials Westudied seventeen patients with precapillary pulmonary hypertension (4 men and 13 women; age, 41±3, ranging from 19 to 61). Results Cardiac output was increased significantly by each system. Pulmonaryvascular resistance was decreased significantly by each system. There was no significant change in mean pulmonaryartery pressure, mean systemic artery pressure, or systemic vascular resistance. The concentrations of NOand nitrogen dioxide (NO2) in the expiratory gas using the pulse delivery system were 0.0 ppmas long as the pulse device was synchronized with the patient's respiratory cycle. Conclusion Inhaled NOusing our pulse delivery system changed the hemodynamicvariables similarly to those whenusing the continuous delivery system. The concentrations of NOand NO2in the expiratory gas using the pulse delivery system were within safe limits. (Internal Medicine 41 : 429-434, 2002)

show abstract

Section: Resultsmentioning

confidence: 99%

Hemodynamic Effects of Inhaled Nitric Oxide Using Pulse Delivery and Continuous Delivery Systems in Pulmonary Hypertension.

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Vazodilatörler, pulmoner arteriyel basıncı ve pulmoner vasküler direnci azaltır, fakat bu ilaçların sistemik (intravenöz) uygulama sonrası gösterdiği etkinin pulmoner damar yatağına özgü olmaması bir sorundur. Küçük klinik çalışmalarda elde edilen verilere göre, nitrik oksit inhalasyonu, PE'li hastalarda hemodinamik durum ve gaz alışverişini düzeltebilir 7,8 . Deneysel ön veriler, akut PE'de levosimendanın, sağ ventrikül-pulmoner arter bağlantısını sağ ventrikül kasılabilirliğini ve pulmoner vazodilatasyon oluşturarak düzenleyebileceğini düşündürmektedir 9 .…”

Section: Akut Dönem Tedavisi Hemodinamik Ve Solunum Desteğiunclassified

Pulmoner Embolinin Güncel Tedavisi

Tekin¹

2016

Arşiv Kaynak Tarama Dergisi

View full text Add to dashboard Cite

Pulmonary embolism remains a major contributor to global disease burden. Risk-adapted treatment and follow-up contributes to a favorable outcome. The recommended definitive treatment for patients with high risk pulmonary embolism is thrombolysis. For patients with a contraindication to anticoagulation and thrombolytic therapy, surgical embolectomy and catheter-based therapies are options. In patients with intermediate-high risk pulmonary embolism, initiation of parenteral anticoagulation is recommended withour delay and thrombolytic therapy should only be given in case of hemodynamic worsening. Finally, direct oral anticoagulants have been shown to be as effective as and safer than the combination of low molecular weight heparin and vitamin K antagonist(s) in patients with low-to intermediate-risk pulmonary embolism. Key words: Pulmonary embolism, thrombolysis, anticoagulation. ÖZETPulmoner emboli küresel hastalık yüküne önemli bir katkıda bulunmaktadır. Risk uyumlu tedavi ve takip olumlu sonuçlar doğurmaktadır. Yüksek riskli pulmoner emboli hastasında tavsiye edilen kesin tedavi trombolizdir. Antikoagülasyon ve trombolitik tedaviye kontraendikasyonu olan hastalarda cerrahi embolektomi ve kateter aracılı tedaviler diğer şeçenektir. Orta-yüksek riskli pulmoner embolide parenteral antikoagülasyon gecikmeden başlanmalı ve hemodinamik kötüleşme olduğu takdirde trombolitik tedavi verilmelidir. Son olarak, düşük-orta riskli pulmoner embolide direkt oral antikoagülanların, düşük molekül ağırlıklı heparin ve K vitamini antagonisti kombinasyonu kadar etkin ve daha güvenli olduğu gösterilmiştir. Anahtar kelimeler: Pulmoner emboli, tromboliz, antikoagülasyon.

show abstract

“…По ре зультатам небольших клинических исследований у больных с ТЭЛА при ингаляции оксида азота мо жет улучшиться гемодинамика и газообмен [266,267]. Предварительно показано, что при использова нии левосимендана может восстановиться баланс между ЛА и ПЖ при острой ТЭЛА за счет сочетания вазодилатации легочных сосудов и повышения со кратимости ПЖ [268].…”

Section: пульмонология 2015; 25 (6): 649-684unclassified

Pulmonary embolism: clinical guidelines of European Society of Cardiology (2014)*

Редакционная¹

2015

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

РезюмеВ данных Клинических рекомендациях суммированы все современные доказательства по диагностике и лечению тромбоэмболии легочной артерии (ТЭЛА). В отличие от предыдущей версии рекомендаций, в данном документе представлены упрощенные варианты клинических прогностических шкал, подробно рассмотрена стратификация риска летального исхода, включая промежуточные степени риска, представлены новые подходы к АКТ, в т. ч. системному тромболизису и катетерным методам лечения, терапии антагонистом витамина К, определено место новых пероральных антикоагулянтов в терапии ТЭЛА. Ключевые слова: рекомендации, тромбоэмболия легочной артерии, венозный тромбоз, шок, гипотензия, торакалгия, одышка, сердеч ная недостаточность, диагностика, антикоагулянты, тромболизис.

show abstract

Inhaled nitric oxide in patients with pulmonary embolism

Cited by 97 publications

References 12 publications

Hemodynamic Effects of Inhaled Nitric Oxide Using Pulse Delivery and Continuous Delivery Systems in Pulmonary Hypertension.

Hemodynamic Effects of Inhaled Nitric Oxide Using Pulse Delivery and Continuous Delivery Systems in Pulmonary Hypertension.

Pulmoner Embolinin Güncel Tedavisi

Pulmonary embolism: clinical guidelines of European Society of Cardiology (2014)*

Contact Info

Product

Resources

About